Study guide
3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis
Key Takeaways Explain This Topic AI
Human placental lactogen is the primary mediator of maternal insulin resistance, and normal pregnancy requires a 200 to 300 percent increase in insulin production to maintain euglycemia.
Glucose crosses the placenta by facilitated diffusion through GLUT-1 but maternal insulin does not, so fetal hyperinsulinemia is the mechanism of macrosomia and neonatal hypoglycemia.
A 50 g glucose challenge result of 200 mg/dL or higher diagnoses gestational diabetes without proceeding to the 3-hour test.
Carpenter-Coustan thresholds on the 100 g 3-hour test are fasting 95, 1-hour 180, 2-hour 155, and 3-hour 140 mg/dL, with two or more abnormal values required for diagnosis.
The one-step 75 g IADPSG protocol uses fasting 92, 1-hour 180, and 2-hour 153 mg/dL, and any single abnormal value is diagnostic, raising detection to roughly 15 to 20 percent versus 6 to 9 percent.
Last updated: September 2026
Pregnancy is a state of engineered insulin resistance, and gestational diabetes is what happens when maternal beta-cell reserve cannot keep pace with it. Understanding which placental hormones drive that resistance, and when they peak, explains both the timing of universal screening and the neonatal consequences of missing the diagnosis.
- Gestational Diabetes Mellitus (GDM): Pathophysiology & Fetal Consequences
- Placental Diabetogenic Hormones
Pregnancy is characterized by progressive physiologic insulin resistance. This adaptation ensures an abundant, continuous flux of glucose across the placenta to meet the energetic demands of the rapidly growing fetus.
Starting in the second trimester, the syncytiotrophoblast secretes increasing quantities of counter-regulatory hormones:
Human Placental Lactogen (hPL): Also known as human chorionic somatomammotropin (hCS), hPL is the primary mediator of maternal insulin resistance. It impairs insulin-stimulated peripheral glucose uptake in skeletal muscle and adipose tissue while promoting maternal lipolysis.
Progesterone & Estrogen: Inhibit peripheral insulin receptor sensitivity and downregulate insulin receptor substrate-1 (IRS-1) signaling.
Placental Growth Hormone (PGH): Modifies maternal insulin sensitivity and hepatic gluconeogenesis.
Cortisol and Prolactin: Further stimulate hepatic glucose production and suppress insulin efficiency.
Tumor Necrosis Factor-alpha (TNF-α): A placental cytokine that directly correlates with insulin resistance in late gestation.
In normal pregnancy, maternal pancreatic beta cells undergo hyperplasia and hypertrophy, increasing insulin production by 200% to 300% to maintain maternal euglycemia. Gestational diabetes mellitus develops when maternal pancreatic beta-cell reserve is inadequate to overcome this pregnancy-induced peripheral insulin resistance.
The Pedersen Hypothesis & Neonatal Sequelae
Glucose crosses the placenta readily via facilitated diffusion using glucose transporter 1 ( GLUT-1 ), whereas maternal insulin does not cross the placenta.
Maternal Hyperglycemia: Leads to persistent fetal hyperglycemia.
Fetal Hyperinsulinemia: By 12 to 14 weeks gestation, the fetal pancreas responds to excessive glucose loads by secreting large amounts of endogenous insulin and insulin-like growth factors (IGF-1).
Accelerated Growth (Macrosomia): Insulin functions as a potent fetal growth hormone, stimulating lipogenesis, glycogen synthesis, and protein accretion. Fetal fat preferentially accumulates in the shoulders and abdominal circumference, resulting in asymmetric macrosomia and a marked risk of shoulder dystocia .
Organomegaly & Cardiac Septal Hypertrophy: Fetal hyperinsulinemia triggers cellular hyperplasia in the liver, spleen, and heart. Subaortic asymmetric septal hypertrophy can lead to transient left ventricular outflow obstruction in the neonate.
Neonatal Hypoglycemia: At birth, the maternal glucose supply is abruptly severed upon cord clamping, but neonatal hyperinsulinemia persists, driving glucose into tissues and causing profound hypoglycemia within the first 1 to 4 hours of life.
Polycythemia and Hyperbilirubinemia: Increased fetal metabolic rate and oxygen consumption induce relative fetal tissue hypoxia, stimulating erythropoietin production. Neonatal polycythemia (hematocrit >65%) increases blood viscosity and, upon red blood cell breakdown, yields hyperbilirubinemia.
Respiratory Distress Syndrome (RDS): Hyperinsulinemia inhibits the synthesis of surfactant proteins (specifically surfactant protein A and B) and lecithin, delaying pulmonary maturation even in late-preterm and early-term infants.
- Screening and Diagnostic Strategies for GDM
- Universal vs. Early Screening
Universal Screening: Conducted for all pregnant individuals between 24 0/7 and 28 6/7 weeks gestation , when placental hormone concentrations rise steeply.
Early Screening (1st Trimester or Initial Prenatal Visit): Recommended for individuals with substantial risk factors: pre-pregnancy BMI ≥30 kg/m², prior GDM, known impaired glucose metabolism (HbA1c 5.7%–6.4%), first-degree relative with Type 2 diabetes, polycystic ovary syndrome (PCOS), or history of delivering a macrosomic infant (≥4,000–4,500 g). Diagnostic criteria in early pregnancy evaluate for undiagnosed pregestational diabetes (e.g., fasting glucose ≥126 mg/dL or HbA1c ≥6.5%).
- Screening Protocols: Two-Step vs. One-Step Approaches [ GDM SCREENING PROTOCOLS ]
- │
- ┌───────────────────────────┴───────────────────────────┐
- ▼ ▼
- [ TWO-STEP APPROACH (ACOG) ] [ ONE-STEP APPROACH (ADA/IADPSG) ]
- Step 1: 50g Non-Fasting GLT Fasting 75g 2-Hour OGTT
- Thresholds: ≥135 or ≥140 mg/dL Fasting: ≥92 mg/dL
- If ≥200 mg/dL: GDM Diagnosed 1-Hour: ≥180 mg/dL
- │ 2-Hour: ≥153 mg/dL
- If 135–199 mg/dL: Proceed to Step 2 │
- ▼ ANY SINGLE abnormal value
- Step 2: 100g Fasting 3-Hour OGTT confirms GDM diagnosis
Carpenter-Coustan Thresholds:
- Fasting: ≥95 mg/dL
- 1-Hour: ≥180 mg/dL
- 2-Hour: ≥155 mg/dL
- 3-Hour: ≥140 mg/dL
- │
- ≥2 abnormal values confirm GDM
- Feature Two-Step Approach (ACOG Standard) One-Step Approach (IADPSG / ADA)
- Initial Test 50-gram oral Glucose Challenge Test (GLT) None; proceeds directly to diagnostic test
- Patient Preparation Non-fasting, arbitrary time of day Strict overnight fast of at least 8 hours
- Screening Threshold Plasma glucose ≥135 or ≥140 mg/dL at 1 hour N/A
- Direct Diagnosis Rule If 50g GLT is ≥200 mg/dL , GDM is diagnosed without Step 2 N/A
Diagnostic Test 100-gram oral Glucose Tolerance Test (OGTT) over 3 hours 75-gram oral Glucose Tolerance Test (OGTT) over 2 hours
Diagnostic Thresholds Carpenter-Coustan Criteria: ; • Fasting: ≥95 mg/dL (5.3 mmol/L); • 1-hour: ≥180 mg/dL (10.0 mmol/L); • 2-hour: ≥155 mg/dL (8.6 mmol/L); • 3-hour: ≥140 mg/dL (7.8 mmol/L) IADPSG Criteria: ; • Fasting: ≥92 mg/dL (5.1 mmol/L); • 1-hour: ≥180 mg/dL (10.0 mmol/L); • 2-hour: ≥153 mg/dL (8.5 mmol/L)
Criteria for Diagnosis Two or more abnormal values (ACOG notes 1 abnormal value identifies an intermediate high-risk cohort) One or more abnormal values
Clinical Impact Lower overall diagnosis rate (~6%–9%), focusing on higher-risk clinical phenotypes Higher diagnosis rate (~15%–20%), detecting milder degrees of glucose intolerance